Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Outlook Therapeutics, Inc. - Common Stock (NQ:OTLK)

1.401 -0.079 (-5.37%)
Streaming Delayed Price Updated: 3:10 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Outlook Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Thursday's session: top gainers and losers
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why
Via Stocktwits
Top 3 Health Care Stocks That Could Blast Off This Month
 
Via Benzinga
Nasdaq Surges 100 Points; Dollar General Earnings Beat Views
 
Via Benzinga
Topics Earnings
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
FDA Rejects Outlook Therapeutics Eye Drug For Second Time
Outlook Therapeutics shares fall after the FDA rejects its ONS-5010 wet AMD drug application, citing insufficient efficacy evidence despite prior trial success. 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
US Stocks Mixed; Nvidia Posts Upbeat Earnings
 
Via Benzinga
Wondering what's happening in today's pre-market session?
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Outlook Therapeutics Reports Q3 Revenue
Via The Motley Fool
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
Rubrik To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Discover the top movers in Friday's pre-market session.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Thursday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.